Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) said, “We continue to enroll patients in each of our three clinical trials as expected, and as planned for. By the end of 2014, we expect to achieve key milestones in each trial. In Q4 we expect to have data from our Phase I trial of Supinoxin in cancer patients with solid tumors. We are also scheduled to complete enrollment of … Continue reading Healthcare ACtive Stocks: Rexahn Pharmaceuticals (NYSEMKT:RNN), Eli Lilly (NYSE:LLY), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD), Gentiva Health Services (NASDAQ:GTIV)